Edward Tenthoff

Yi Chen

Michael Petusky

Yale Jen

James Stamos

Maurice Raycroft

Destiny Buch

- On **September 15, 2025**, OPKO Health, Inc. completed the sale of select oncology and oncology-related clinical testing services businesses of its subsidiary, BioReference Health, to Labcorp.  **[944809_0001193125-25-203530_opk-20250915.htm:0]** **[944809_0001193125-25-203530_opk-ex99_1.htm:0]** **[944809_0001193125-25-203530_opk-20250915.htm:1]** 
- The total purchase price for the transaction is up to **$225 million**, including **$192.5 million** paid at closing and up to **$32.5 million** in a contingent earnout based on performance.  **[944809_0001193125-25-203530_opk-ex99_1.htm:0]** **[944809_0001193125-25-203530_opk-20250915.htm:1]** 
- BioReference Health will retain its core clinical testing operations in the New York and New Jersey region and its **4Kscore® Test franchise**, which generated approximately **$300 million in revenue for 2024**.  **[944809_0001193125-25-203530_opk-ex99_1.htm:0]** 
- OPKO intends to utilize a portion of the proceeds from the sale to fund its **recently expanded share repurchase authorization**.  **[944809_0001193125-25-203530_opk-ex99_1.htm:0]**

OPKO Health Completes Sale of BioReference Health's Oncology and Clinical Testing Businesses to Labcorp

- Entera Bio, in collaboration with OPKO Health, presented positive preclinical pharmacokinetic data for their oral GLP-2 analog, OPK-8801003, for Short Bowel Syndrome (SBS) at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress on **September 15, 2025**.  **[944809_c3c40d73b5f84d5082b10717bceb8b74_0]** 
- The OPK-8801003 GLP-2 tablet demonstrated an **extended half-life of approximately 15 hours** in minipigs, an 18-fold improvement over teduglutide, and robust oral bioavailability with peak plasma concentrations reaching ~**200 ng/ml** (Cmax).  **[944809_c3c40d73b5f84d5082b10717bceb8b74_0]** 
- This oral tablet candidate aims to provide a less-invasive administration for the approximately **30,000 SBS patients** who currently rely on daily injections of Gattex®, which generates approximately **$800 million** in annual sales.  **[944809_c3c40d73b5f84d5082b10717bceb8b74_0]** **[944809_c3c40d73b5f84d5082b10717bceb8b74_1]**

OPKO HEALTH (OPK)